Biotechnology

Origin Agritech Announces Addition to Two FTSE Russell Equity Indices

BEIJING, Sept. 12, 2022 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that effectiveSeptember 16, 2022, Origin Agritech will be added two new equity indices, the FTSE Micro Cap Index and the FTSE Total Cap Index...

2022-09-12 20:45 2069

Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac Neurosurgical Robot

HSINCHU, Sept. 12, 2022 /PRNewswire/ -- Brain Navi, the leading surgical robot manufacture inTaiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region,Jordan, Egy...

2022-09-12 08:31 2145

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients * For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% * Lemzoparlimab does not require priming ...

2022-09-10 21:00 1728

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...

2022-09-09 20:00 1458

Antengene to Present at Upcoming Industry Conferences

SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...

2022-09-09 14:43 1031

MGI Celebrates Grand Opening of Its New State-of-the-Art Demo Lab in Japan

TOKYO, Sept. 9, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, announced today on its first day of IPO inChina the grand opening of a new demonstration laboratory inTokyo, Japan, enhancing Japanese customers' experience. MGI has been expanding the oper...

2022-09-09 09:00 2264

KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO

SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation a...

2022-09-09 06:00 2228

YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine

BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics, announced that the Company received the approvals from the re...

2022-09-08 21:33 2342

Nutromics raises US$14 million for its ground-breaking wearable diagnostic platform

MELBOURNE, Australia and SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Global MedTech start-up Nutromics has raised an additional US$14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion acrossAustralia and the United States. Strategic in...

2022-09-08 20:54 2161

ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS

* International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics * The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the ...

2022-09-08 16:41 1436

Cytiva launches BioChallenge in Southeast Asia to support biotech startup development

* Cytiva's BioChallenge launches in Singapore, Indonesia, Thailand and Vietnam to accelerate the growth of promising emerging biotechs * BioChallenge facilitates access to Cytiva's services and expertise to scale up efficiently, mitigate risks and reduce time to go to market * Application pe...

2022-09-08 15:31 2186

The Outbreak of COVID-19 Unlocked the Demand for Antimicrobial Technologies

Innovations triggered by the pandemic are pushing industries to adopt long-lasting antimicrobial technology, says Frost & Sullivan SAN ANTONIO, Sept. 8, 2022 /PRNewswire/ -- The outbreak of COVID-19 unlocked the demand for antimicrobial technologies across sectors, finds Frost & Sullivan's recen...

2022-09-08 15:12 1566

Innovent's Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients with EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Second Interim Analysis Results of the ORIENT-31 Study

ROCKVILLE, Md. and SUZHOU, China, Sept. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology...

2022-09-08 08:05 3010

InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

NANJING, China, Sept. 7, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study ...

2022-09-08 08:00 1533

Sangel Capital Founder Receives Title of China's Top Early-Stage Investor from ChinaVenture Awards

SHENZHEN, China, Sept. 7, 2022 /PRNewswire/ -- Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China, has announced that Liu Mulong, Founding Partner with the Company, has been awarded as one ofChina's top early-stage investors of 2021 ...

2022-09-07 23:30 3146

NOVAMONT GROUP: NEW CEO FOR OUR 100% OWNED BIOBAG GROUP

NOVARA, Italy, and ASKIM, Norway, Sept. 7, 2022 /PRNewswire/ -- The Board of BioBag International AS has appointed Patrik Fogelström as new CEO of the BioBag Group and Managing Director of the parent company BioBag International AS, which from 2021 are part of Novamont Group, an international lea...

2022-09-07 21:07 4760

Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board

NEWARK, Del., Sept. 7, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a  global R&D biotechnology company, today announced the appointment ofRakesh Dixit , Ph.D., DABT to its Advisory Board to advance Antibody Drug-Conjugates (ADCs) for the treatment of solid tumor cancers in Biosion's pipeline. ...

2022-09-07 20:54 2752

TikoMed's drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action

VIKEN, Sweden, Sept. 7, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company's lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African a...

2022-09-07 14:32 2599

Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds

MILAN, Sept. 7, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown. The Barrie...

2022-09-07 06:01 3229

Hummingbird Bioscience to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive OfficerPiers Ingram, Ph.D., and Chief Financial Office...

2022-09-06 20:00 2092
1 ... 107108109110111112113 ... 275

Week's Top Stories